Monday – Friday 10.00a.m. – 19.00p.m.

Market Analysis of Anticoagulants in India

Release date 01.02.2021

Number of pages 56

Formats DOCX, PDF

Cost 45000 ₹

Buy it Now

Order a Report Update

The relevance of research

Anticoagulants are drugs designed to reduce blood clotting and thereby restore its fluidity (rheological properties) and reduce the risk of recurrent thrombosis.

Anticoagulants are used as part of the treatment of pathologies of the cardiovascular system at the risk of thrombosis, with extensive surgical interventions, to prevent blood clotting, for the prevention and early (acute) treatment of thrombosis and embolism. Drugs related to anticoagulants are prescribed for both therapeutic and prophylactic purposes.

Purpose of the study

Analysis of the state of the anticoagulant market, assessment of the market size, analysis of competitors, as well as identification of factors affecting the anticoagulant market

Content

Part 1. Overview of the Indian anticoagulant market

1.1. Main characteristics of the market
1.2. Dynamics of the market volume of anticoagulants 2015-2019 Potential market capacity
1.3. Assessment of factors affecting the market
1.4. Life cycle stage of the anticoagulant market
1.5. Competition from substitute products

Part 2. Competitive analysis in the anticoagulant market

2.1. Major players in the market
2.2. Market shares of the largest competitors
2.3. Profiles of major players

Part 3. Analysis of the production of anticoagulants

3.1. Volume and dynamics of domestic production of anticoagulants
3.2. Share of exports in the production of anticoagulants
3.3. Segmentation of anticoagulant production by regions
3.3.1. Production by Union Territories
3.3.2. Production by states of India

Part 4. Analysis of foreign trade supplies of anticoagulants

4.1. Volume and dynamics of imports of anticoagulants
4.2. Import structure
4.3. Volume and dynamics of export of anticoagulants
4.4. Export structure

Part 5. Anticoagulant consumption analysis

5.1. Dynamics of consumption of anticoagulants
5.2. Analysis of the results of tenders for the purchase

Part 6. Price Analysis

6.1. Average producer prices by union territories
6.2. Average consumer prices by states in India

Part 7. Assessment of factors of investment attractiveness of the market

Part 8. Market forecast for anticoagulants until 2024

Part 9. Recommendations and conclusions

Research excerpt

Part 1. Overview of the Indian anticoagulant market

1.1. Main characteristics of the market

Anticoagulants are drugs designed to reduce blood clotting and thereby restore its fluidity (rheological properties) and reduce the risk of recurrent thrombosis. Anticoagulants reduce the activity of tissue (fibrinogen, platelets) or plasma coagulation factors.

Drugs related to anticoagulants are prescribed for both therapeutic and prophylactic purposes. They are available in the form of tablets, capsules, ointments and solutions for intravenous and intramuscular administration. The doctor prescribes anticoagulants, choosing the dosage necessary for the patient.

The history of the creation of anticoagulant drugs is connected with the fact that in the 1920s a new disease in cattle was discovered in North America. It occurred when feeding spoiled clover hay and consisted of severe internal hemorrhages, which often led to the death of animals. It turned out that when such hay is spoiled, the toxic substance dicumarol is formed, which has the ability to thin the blood and sharply reduce its clotting, so that even a slight wound causes constant bleeding and, as a result, large blood loss. In 1939-1941. Canadian surgeon G. Murray and Swedish surgeon C. Clafoord first used heparin for the prevention of postoperative thrombosis, although the first and not entirely successful experience was already in 1924.

Anticoagulants are prescribed for the treatment of:
Acute venous and arterial thrombosis.
Pathologies associated with the release of a large amount of thromboplastic substances from tissues.
After previous surgeries to prevent blood clots.
As a preventive measure in the presence of heart disease.

Modern pharmacology offers patients synthetic anticoagulants, of which there are a large number at the moment. Such a wide selection of drugs allows you to choose the most effective and effective medication in each case.

The Federal Law ""On the Circulation of Medicines"" provides for the following types of names used in relation to medicines and pharmaceutical substances:
International non-proprietary name of a medicinal product (hereinafter referred to as INN) is the name of the active substance of a pharmaceutical substance recommended by the World Health Organization.

Trade name of a medicinal product - the name of a medicinal product assigned by its developer, holder or owner of the registration certificate.
There are two groups of anticoagulants depending on their action: direct (rapid action) and indirect (long-acting). Anticoagulants of direct action, in turn, are divided into anticoagulants for parenteral administration and oral.

Consider the characteristics of some drugs - anticoagulants:
Heparin (INN - Sodium Heparin) is one of the most common drugs in this area. Heparin prevents platelets from sticking together, increases blood flow to the kidneys and heart muscle. Taking the drug allows you to reduce blood pressure, has an anti-sclerotic effect, increases the permeability of the vascular wall, and does not allow smooth muscle cells to carry out proliferative processes. If the drug is used to prevent thrombosis, then it is administered subcutaneously. In emergency cases, Heparin is administered intravenously. You can also use gels and ointments, which contain Heparin.

Fraxiparine (INN - Calcium Nadroparin) - is based on the use of the calcium salt of heparin. It is used by surgeons and anesthesiologists during operations, prescribed by therapists for the prevention of blood clots and the treatment of vascular ailments. Available in ampoules for injection.

Clexane (INN - Enoxaparin sodium) - usually used after an acute heart attack. Not only prevents the formation of blood clots, but also reduces pressure and a feeling of heaviness in the legs. Available only in ampoules for injection. Its use is possible only under the supervision of a doctor in a hospital, because it acts strongly and can cause internal bleeding.

Fragmin (INN - Dalteparin sodium) is a clear or yellowish solution that has a mild effect on platelet adhesion and primary hemostasis. It is forbidden to enter intramuscularly. Fragmin in high doses is prescribed to patients immediately after surgery, especially those who have a high risk of bleeding and platelet dysfunction.

Eliquis (INN - Apixaban) is a direct-acting anticoagulant that inhibits the activity of blood coagulation factor Xa (FXa), reversibly and selectively blocking the active site of the enzyme. It does not have a direct direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin.

Xarelto (INN - Rivaroxaban) is an oral anticoagulant from the group of direct factor Xa inhibitors. Developed and manufactured by the German pharmaceutical company Bayer. Indications: prevention of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation, treatment of deep vein thrombosis and pulmonary embolism, and prevention of recurrent DVT and PE.

Warfarin (INN - Warfarin) is an anticoagulant agent that blocks the synthesis of blood coagulation factors in the liver, reduces their concentration in plasma and slows down the process of thrombosis. Warfarin is characterized by an early effect and a rapid cessation of undesirable effects when the dose is reduced or the drug is discontinued.

It is impossible to say unequivocally which drugs are better and more preferable, since everything depends on the specific clinical case.
...

1.2. Dynamics of the market volume of anticoagulants 2015-2019 Potential market capacity

Consider the dynamics of the volume of the anticoagulant market in India in real terms for the period from 2015 to 2019.

Diagram 2. Dynamics of the market volume of anticoagulants, 2015 – 2019, mln packs

For the period from 2015 to 2019, the dynamics of the volume of the anticoagulant market has a wave-like character.
...

As for the potential capacity of the anticoagulant market in the medium term, it depends on the incidence of diseases of the circulatory system in the population. This category of drugs is mostly dispensed by prescription, since the appointment of one or another anticoagulant depends on the specific disease, the general condition of the patient and the presence of concomitant abnormalities, therefore the most appropriate medication is selected by a specialist.

Calculation of the distribution of revenue across the Union Territories was made by GidMarket on the basis of data on the production of anticoagulants in the Union Territories, on imports and exports from / to federal districts.

The distribution of shares between federal districts in terms of sales proceeds is stable.

1.3. Assessment of factors affecting the market

Let's consider the main factors influencing the market and, accordingly, the demand for anticoagulants: economic, social, political and technological factors.

Economic forces

The market for anticoagulants is a commodity market with a high share of imports, so it is significantly influenced by the dynamics of the dollar.

The fall in the rupee, which began in the fourth quarter of 2014, largely due to lower oil prices, put pressure on consumer activity, which was reflected in lower demand, lower retail sales, lower investment, rising unemployment and falling household incomes.
...

Number of pharmacy establishments in India

One of the main channels for the sale of anticoagulants are pharmacies through which drugs are sold to the Indian population.
...

Emergence and development of pharmaceutical clusters
One of the main tasks of the pharmaceutical industry is to get away from import dependence and create our own laboratories and factories for the development and production of effective and safe drugs, and in cooperation with the world's leading manufacturers, and completely unique Indian developments.

Pharmaceutical clusters in the country are being created to expand the capabilities of the national pharmaceutical industry. First of all, the advantages of cluster development are associated with the synergistic effect of their activities. The most obvious effect in pharmaceutical clusters is achieved by sharing the infrastructure of pharmaceutical clusters, and not only engineering, but also research and education. For example, it becomes possible to collectively use established research centers, laboratories capable of conducting preclinical studies of drug prototypes, collections of strains, drug quality control centers, and other companies providing outsourcing services.

Pandemic COVID-2019
A universal, effective drug for coronavirus has not yet been developed. In this regard, doctors take a comprehensive approach to solving the problem. In most cases, therapy is carried out with an emphasis on symptomatic treatment.

The main task of physicians is to facilitate the patient's well-being and maintain the basic vital functions of the internal organs.

With coronavirus infection, the problem of preventing vascular thrombosis at all levels is combined with thrombocytopenia and high risks of consumption coagulopathy (DIC) in the late stages of the disease. Therefore, the appointment of direct and indirect anticoagulants at all stages of outpatient and inpatient treatment is of particular relevance.

Clinical observations have shown that COVID-19 is associated with an increase in blood clotting mechanisms. It is known that in patients with coronavirus, there is an increase in the concentration of D-dimers, which cause increased thrombosis. In this regard, thrombotic complications are often recorded in patients with COVID-19, accompanied by the formation of large blood clots.

To avoid this, doctors decided to include anticoagulants in the treatment algorithm - the list of drugs for coronavirus was supplemented by this group of drugs. For treatment, both oral anticoagulants and low molecular weight and fractionated heparin are used, which are administered subcutaneously. What drugs to take with a coronavirus person in a particular case is decided by the doctor.
...

Social factors

Morbidity of the population
Anticoagulants are drugs that inhibit the activity of the blood coagulation system and prevent the development of the thrombus formation process. They are used as part of the treatment of pathologies of the cardiovascular system at the risk of thrombosis, with extensive surgical interventions, to prevent blood clotting.

During the period under review, there has been an increase in the incidence of diseases of the circulatory system in India.

Diseases of the circulatory system occupy the second place in the overall structure of the incidence of the population of India.

Mortality of the population

Cardiovascular disease ranks first among the pathological causes leading to the death of the population in India. Often, blood clots lead to the death of a person suffering from cardiac pathology. In almost every second person, a blood clot is found in the vessels during an autopsy.
...

Real disposable money income of the population
The main sales channel for anticoagulants is the commercial segment, in particular, the sale of drugs through pharmacy chains. In this regard, the slowdown in the growth of the purchasing power of the population due to the stagnation of real disposable income has a negative impact on the consumption of medicines in this market segment.
...

Technological factors

Scientific and technological progress of the industry

Pharmaceutical progress does not stand still. Not only in India, but also in the world, the development of the best and most effective anticoagulant, with a minimum number of contraindications and side effects, continues.

First of all, when synthesizing new drugs, scientists are trying to achieve the following improvements:
universality, that is, the ability to take one drug for different diseases;
the presence of an oral form;
increasing the controllability of hypocoagulation, minimizing additional control;
no need for dose adjustment;
expanding the range of potential patients for whom taking this medication is necessary, but was contraindicated;
the possibility of taking an anticoagulant by children.

The emergence of modern anticoagulant preparations and the continued development in this area speaks of the constant development of the market.

Implementation of IT technologies in the industry

Thanks to the development of modern technologies, the availability of information is increasing. So, for example, the developers introduced a free application for smartphones, thanks to which you can check the authenticity of the purchased medicine.

The application is called “Honest Sign”, its presentation was held as part of the All India Patients Congress in 2019.

Using the camera, the smartphone “reads” the Data Matrix digital marking code on the drug package, the program processes the information and displays the test result. Since all information about the drug, ""encrypted"" in the code, is also contained in the general database of all drugs on the market, using the application, the buyer will be able to see the current status of the specific package he is purchasing and make sure that this is not a counterfeit, but a legally produced product. If the code is not found in the system, this may indicate violations in the circulation of medicines. The buyer will be able to immediately report this to the supervisory authorities using the application - for this, the application provides a special form.

Political factors

Labeling of medicinal products

Paragraph 5 of the List of Instructions of the President of India, following a meeting with members of the Government of India dated 04.02.2015, instructed to ensure the development and phased implementation of an automated system for monitoring the movement of medicines (MDLP) from the manufacturer to the end consumer using labeling (codification) and identification of packages of medicines in in order to ensure effective quality control of drugs in circulation and combat their falsification.

The main goals of labeling and monitoring the movement of medicines.

For the state:
prevention of entry into circulation and simultaneous withdrawal from circulation in an automated mode throughout India of substandard, as well as falsified and counterfeit drugs at any stage of their circulation from the manufacturer to the end user;
prevention of inefficient spending and saving budgetary funds due to the impossibility of implementing schemes for the ""repeated injection"" of medicines, the impossibility of legal sale of medicines subject to subject-quantitative accounting, as well as those not intended for retail sale;
control over the targeting of the movement of drugs purchased at the expense of the budget, the cost of their purchase; monitoring pricing and marginal retail prices for medicines from the Vital and Essential Drugs List;
operational planning and management of stocks and reserves of drugs at all levels, including the strategic one.

For the population:
the ability to personally check the legality of the purchased (received) medicinal product using a personal mobile device.

For business:
cost reduction due to more efficient logistics management; reduction of lost profits due to counterfeit and counterfeit products; compliance with the requirements for the supply of products to international markets.

Terms of monitoring the movement of medicines for medical purposes:
- from July 1, 2019, registration of turnover participants began on the official website of Chestnyznak.rf.
...

Industry experts also insist on legislative approval of personal responsibility, including for the operator of the Center for the Development of Advanced Technologies. Victor Dmitriev noted that “today it is not clear who will be responsible for failures in the country's drug supply, and even worse if people suffer as a result of technical errors and lack of prompt response.”

Registration of medicines
To bring a medicinal product to the pharmaceutical market in India, it is necessary to register it by obtaining a marketing authorization (MA).

Registration is a state examination of quality and an examination of the relationship between the expected benefit and the possible risk of using a medicinal product with the aim of subsequently authorizing the medical use of the drug in India.
The main regulatory document regulating the procedure for registering medicines is Federal Law No. 61-FZ “On the Circulation of Medicines” dated April 12.04.2010, .

The following categories of drugs are subject to state registration:
medicines being introduced for the first time in India;
Medicinal products previously registered but manufactured in other dosage forms in accordance with the list of names of dosage forms, in a new dosage with evidence of its clinical significance and effectiveness;
new combinations of previously registered drugs.

Registration of medicines and pharmaceutical substances is entrusted to the Ministry of Health of India. For state registration or amendments, the applicant pays the state fee to the personal account of the Ministry of Health of India.

In accordance with Law No. 61-FZ ""On the Circulation of Medicines"", the registration period is 210 business days. This period does not include the time required to conduct the clinical trial.

The drug registration process consists of 2 main consecutive stages: pre-registration procedures and drug registration. Each stage includes several parallel sub-items:

Stage 1. Pre-registration stage:
1.1. GMP inspection of the manufacturer by Indian inspectors of the Ministry of Industry and Trade of India.
1.2. Clinical trial of drug in India.
1.3. Preparation of a registration dossier in the format of a general technical document and preparation of drug samples for registration examination.

Stage 2. Registration of the medicinal product:
2.1. Examination of the quality of the medicinal product.
2.2. Examination of the ratio of the expected benefit to the possible risk of using the drug.
The second stage of the registration procedure ""registration of a medicinal product"" can only be started if the results of all the procedures of the first stage are available.

At the first registration of the drug in India, the MA is issued for 5 years. After this period, the manufacturer submits documents to confirm the registration of the drug, and then the registration certificate is issued indefinitely.

Registration of drugs remains a laborious and lengthy process, requires significant financial investments, as a result of which this factor has a deterrent effect on the development of the anticoagulant market. At the same time, it is important to understand that it is unacceptable for low-quality and unsafe drugs to enter the market, so the duration and complexity of drug registration can be justified to some extent.

Patent system
Drugs are divided into two groups - original and generics. Original - these are the preparations of the manufacturer, who was the first to bring out the molecule of the active substance and received a patent. Generics are a generic drug containing a chemical substance - an active pharmaceutical substance that is identical to a previously invented and patented by another company. A patent is a form of insurance for innovative pharmaceutical companies.
...

State development programs
As part of the development of the pharmaceutical industry in India, the Indian Pharmaceutical Industry Development Strategy 2009 was approved in 2020 to support Indian drug manufacturers. In order to further develop the industry, the Ministry of Industry and Trade of India has developed a draft order of the Government of India ""On the Approval of the Strategy for the Development of the Pharmaceutical Industry of India for the period up to 2030"".

The main goal of India's state policy for the development of the pharmaceutical industry for the period up to 2030 is to guarantee India's security in the field of drug supply to the population and drug availability in all segments, to ensure an advanced level of scientific, technical and technological development of the pharmaceutical industry, to create an export-oriented potential of the pharmaceutical industry, availability of competencies in research and development, full-cycle production, introduction into clinical practice and export of innovative medicines.

Expected results of the implementation of the Strategy:
1. A significant increase in the volume and range of production of pharmaceutical products to ensure the domestic market and the development of exports of finished forms of medicinal products and pharmaceutical substances.
2. Implementation of modern digital platforms in the industry and the best regulatory practices in the pharmaceutical industry.
3. Meeting the needs of the healthcare system and the population in accordance with the designated state priorities, as well as in the most expensive or voluminous niches of the pharmaceutical market.
4. Creation of a personnel training system to meet the needs of the pharmaceutical industry, including a developed educational and scientific infrastructure, including through the creation of consortiums with technology partners.
5. Development of innovative, technical and technological infrastructure, increase in the share of intangible assets of companies, including to increase the export of pharmaceutical products.
...

Public procurement of medicines
The state purchases medicines for hospitals and citizens of the privileged category who receive medicines under a quota. The Ministry of Health, regional departments or the hospitals themselves are directly engaged in procurement. They publish information about the upcoming procedure in the Unified Information System (UIS) and necessarily indicate the initial maximum contract price (IMCC). This amount should be formed taking into account the market situation, and the procedure for determining the NMCC should comply with the norms of the law.
...

Let's present the results of the analysis of factors influencing the market in the form of a STEP-analysis table.

Table 2. STEP analysis of factors influencing the anticoagulant market

Thus, at the moment, the Indian market of anticoagulants is experiencing a generally positive influence of environmental factors of medium strength.
...

1.4. Life cycle stage of the anticoagulant market

Currently, the anticoagulant market is at the stage of life cycle maturity. Products on the market are represented by a large number of drug names, brands, both foreign and Indian, various dosage forms (tablets, injections, capsules).
...

During the period of implementation of the state program ""Development of the pharmaceutical and medical industry"" for 2013-2020, the purpose of which was to establish the production of full-cycle medicines in India, localize production and stimulate the development of innovative technologies, conditions were created for the development of the pharmaceutical industry market. This resulted in significant industry growth during the initial periods of the program.
...

1.5. Competition from substitute products

When abnormalities in the work of the cardiovascular system are detected and as a prevention of thrombosis, doctors prescribe regular intake of drugs to thin the blood. Many varieties of drugs in this area are conditionally divided into two groups: antiplatelet agents (prevent platelet adhesion, inhibit vascular-platelet hemostasis) and anticoagulants (block plasma coagulation factors and prevent the formation of a fibrin clot).

Antiplatelet agents are drugs that prevent cell aggregation (clumping) and prevent the formation of blood clots. They are given to people who are at high risk for blood clots. Antiplatelet agents have a milder effect.

Treatment with antiplatelet agents is prescribed:
with ischemic heart disease;
after a heart attack;
patients with rhythm disturbances;
secondary prevention of blood clots in stroke or TIA survivors;
primary prevention in individuals at high risk of complications;
after any operations on the heart and blood vessels;
patients with peripheral arterial disease.

Antiplatelet agents prevent platelets from sticking together and accumulate near the walls of blood vessels. For example, with an injury to the skin, platelets perform a natural process - they form a blood clot in the wound area and stop bleeding.

In pathological processes, platelets form blood clots in the vessels. It is in such cases that long-term use of antiplatelet agents is necessary.

The difference between anticoagulants and antiplatelet agents in principle and the severity of the action, the number of side effects. At the first signs of blood clotting, it is advisable to use antiplatelet agents, they have a mild effect and an affordable price, they can be taken for a long period for preventive purposes, as well as during the rehabilitation period. Anticoagulants have a higher pricing policy. Their action is considered more stringent. With long-term use, the likelihood of side effects is higher than that of antiplatelet agents.

Antiplatelet agents include:
Acetylsalicylic acid (Aspirin-cardio, Cardiomagnyl, Tromboass, Acecardol, etc.);
Clopidogrel (Plavix, Plagril, Zilt, etc.);
Ticagrelor (Brilint);
Prasugrel (Effient);
Dipyridamole (Curantil);
Ticlopidin (Tiklid);
Eptifibatide (Integrillin).
Anticoagulants and antiplatelet agents are prescribed both in combination and in monotherapy, therefore, it is impossible to consider antiplatelet agents as anticoagulant substitute products in the full sense of the word. Medicines are prescribed only by the attending physician with periodic testing of the results, therefore, if it is necessary to take anticoagulants, substitute products cannot be considered in this case, and therefore, competition from substitute products is weakly expressed.

Part 2. Competitive analysis in the anticoagulant market

2.1. Major players in the market

The Indian market of anticoagulants is represented by foreign brands, whose share in value terms is ...%.
...

2.2. Market shares of the largest competitors

Estimation of market shares of anticoagulants was carried out by GidMarket on the basis of import volumes of foreign medicines, export volumes, revenues of Indian manufacturers, taking into account adjustments for the company's activities and manufactured nomenclature.
...

2.3. Profiles of major players

XXX
...
XXX
...
XXX
...

Part 3. Analysis of the production of anticoagulants

3.1. Volume and dynamics of domestic production of anticoagulants

Consider the dynamics of the production of anticoagulants in India.

Diagram 10. Dynamics of production volumes of anticoagulants in India for 2015 - 2019, million Rs.

The main Indian manufacturers of anticoagulants are:
...

The dynamics of the total revenue of the leaders among the Indian manufacturers of anticoagulants is linear.

3.2. Share of exports in the production of anticoagulants

Thus, Indian manufacturers of anticoagulants are currently focused on meeting domestic market needs. Export potential is an important part of the national economy, its formation is necessary for the development of the country, increasing the competitiveness of domestic products, interethnic relations between the countries of the world, in connection with which, the development of this area is one of the strategic tasks within the framework of the draft Indian Pharmaceutical Industry Development Strategy for the period up to 2030.

3.3. Segmentation of anticoagulant production by regions
3.3.1. Production by Union Territories

Table 5. Dynamics of production of anticoagulants in India by union territories in 2015-2019, million Rs.

The leader among the federal districts in the production of anticoagulants during the entire period under review is the Central Federal District ...

3.3.2. Production by states of India
...

The regional distribution of the pharmaceutical industry in India has developed under the influence of a complex of factors. Pharmaceutical and chemical industries are characterized by multi-stage technological processes and their energy and material consumption. In this regard, production data must be placed near sources of cheap energy, significant water resources, etc.

Part 4. Analysis of foreign trade supplies of anticoagulants

4.1. Volume and dynamics of imports of anticoagulants

Consider the indicators of foreign trade operations on the market of anticoagulants in India.

Diagram 14. Volume and dynamics of imports of anticoagulants to India in kind in 2015-2019, thousand packs

The dynamics of imports of anticoagulants in physical terms is undulating.
...

The dynamics of imports of anticoagulants in value terms is somewhat different from changes in the indicator in physical terms.
...

4.2. Import structure

Consider the structure of imports by imported drugs in 2019.

4.3. Volume and dynamics of export of anticoagulants
...

The dynamics of exports in value terms is growing.
...

Diagram 19. Balance of exports and imports in the market of anticoagulants in India in 2014-2019, thousand packs

During the period under review, the trade balance (difference between exports and imports) in the anticoagulant market in India remains...

4.4. Export structure

In 2019, more than ...% of anticoagulants were exported to the CIS countries. The leaders among exporting countries are ...

Part 5. Anticoagulant consumption analysis

5.1. Dynamics of consumption of anticoagulants

The volume of consumption of anticoagulants is calculated in value terms based on the market volume in consumer prices.
The dynamics of changes in the consumption of anticoagulants is growing.

5.2. Analysis of the results of tenders for the purchase

For the period from 01.01.2020 to 31.10.2020, contracts for the purchase of anticoagulants were concluded for a total amount of more than ... billion rupees ... This jump is associated with several factors: the purchase of anticoagulants during the pandemic, as well as positive changes in the state regulation of order procurement of medicinal products, in particular, in determining the initial maximum price of the contract.
...

The top three among medicines procured under tender procedures for the segment of public institutions occupies a total share of ...% - these are Xarelto, Eliquis and Fraxiparine.
...

Part 6. Price Analysis

6.1. Average producer prices by union territories

Some anticoagulants are included in the list of vital and essential drugs (VED), determined by the Government of India in accordance with the order of October 12, 2019 N 2406-r for the purpose of state regulation of prices for medicines. The main anticoagulants considered in the framework of this study are included in the specified list, and therefore the average producer prices are determined according to the State Register of Prices for Vital and Essential Drugs.

Table 9. Average producer prices on the anticoagulant market in the Union Territories in 2019, Rs./pack

When considering manufacturer prices for anticoagulants, it should be borne in mind that prices differ significantly in terms of the active substance of the drug, the dosage form of release, and the volume of packaging.
...

6.2. Average consumer prices by states in India

In order to more visually assess the change in consumer prices in the states of India, prices are given for the anticoagulant - Heparin sodium, dosage form - gel for external use 1000 IU / g.
...

Part 7. Assessment of factors of investment attractiveness of the market

The positive factors of the investment climate of the market dominate over the negative ones.
...

The most significant positive factors.
...

The most significant negative factors.
...

Part 8. Market forecast for anticoagulants until 2024

We will analyze the market based on methods based on identifying trends over time, adjusted for expert opinion in the industry.

The relevance of prescribing anticoagulants in the short term will mainly be determined by the increase in demand as a result of the spread of coronavirus infection in India.

Most of those infected with coronavirus have a mild illness. But there are people who, against the background of an infectious process, develop life-threatening conditions, including thrombosis of small and large blood vessels. To avoid complications, doctors prescribe blood thinners for coronavirus. The list of anticoagulants includes tablets and injections.

Among the many complications that the coronavirus causes, thrombosis is of particular danger. The formation of a clot that can block blood flow occurs due to several factors. Among them:
- thickening of the blood against the background of high temperature and insufficient fluid intake;
- excessive activity of the compliment system (a protein complex that recognizes viruses and cleanses the blood of dead cells);
- damage to the endothelial layer of blood vessels by the virus.
...

In addition, the annual increase in the incidence of the population, the development of technologies in the pharmaceutical industry, the purchase by consumers of prescription drugs (most anticoagulants are available only by prescription) due to falling incomes, the implementation of government programs, etc. contribute to the increase in the market volume.

Part 9. Recommendations and conclusions

Thus, based on the totality of the analysis of these prospects and forecasts, it is recommended that new enterprises enter the anticoagulant market in the short term.
...

For companies already operating in the market and companies that will enter the market in the coming year, the following is recommended:
...

Diagrams

Diagram 1. The ratio of imported and domestic products in the anticoagulant market in India in 2014-2019 in value terms, %
Diagram 2. Dynamics of the market volume of anticoagulants, 2015 – 2019, mln packs
Diagram 3. Revenue (net) from the sale of anticoagulants by union territories for 2014 - 2019,
Chart 4. Monthly dynamics of the US dollar against the rupee, 2015-2020 (Jan-Oct), Rs. for 1 US dollar
Diagram 5. Dynamics of the number of pharmacies in India, 2014 - 2019, thousand units
Diagram 6. Dynamics of the incidence of the population in India with diseases of the circulatory system in 2010-2019, million people
Diagram 7. The proportion of deaths from diseases of the circulatory system in India in 2019,%
Diagram 8. Dynamics of real incomes of the population of India, 2014-2019, % to the previous year
Diagram 9. Shares of the largest competitors in the anticoagulant market in 2019
Diagram 10. Dynamics of production volumes of anticoagulants in India for 2015 - 2019, million Rs.
Diagram 11. Dynamics of the total revenue of the largest manufacturers (TOP-5) of anticoagulants in India, 2015 - 2019, billion Rs.
Diagram 12. The share of exports in production for 2015–2019, %
Diagram 13. Structure of production of anticoagulants by states of India in 2019, %
Diagram 14. Volume and dynamics of imports of anticoagulants to India in kind in 2015-2019, thousand packs
Diagram 15. Volume and dynamics of imports of anticoagulants to India in monetary terms in 2015-2019, mln USD
Diagram 16. Structure of imports of anticoagulants by drug names in 2019, mln USD
Diagram 17. Dynamics of export of anticoagulants from India in kind in 2015-2019, thousand packs
Diagram 18. Dynamics of export of anticoagulants from India in monetary terms in 2015-2019, mln USD
Diagram 19. Balance of exports and imports in the market of anticoagulants in India in 2014-2019, thousand packs
Chart 20. Structure of exports by countries in 2019 in value terms, %
Diagram 21. Dynamics of consumption of anticoagulants in monetary terms, 2015 - 2019, billion Rs.
Diagram 22. Structure of tenders for purchased groups of anticoagulants in value terms in 2019, %
Chart 23. Anticoagulant market volume forecast in 2020 - 2024, mln packs

Tables

Table 1. Main characteristics of the group of anticoagulants
Table 2. STEP analysis of factors influencing the anticoagulant market
Table 3. Main companies participating in the anticoagulant market in 2019
Table 4. Profiles of companies participating in the anticoagulant market in 2019
Table 5. Dynamics of production of anticoagulants in India by union territories in 2015-2019, million Rs.
Table 6. Structure of imports of anticoagulants by importing countries in 2019, units rev.
Table 7. Contracts for tenders for the purchase of anticoagulants concluded from 01.01.19/31.12.19/10 to / / in the amount of more than million Rs.
Table 8. TOP-10 main drugs purchased through tenders - anticoagulants in 2019
Table 9. Average producer prices on the anticoagulant market in the Union Territories in 2019, Rs./pack
Table 10. Average consumer prices in the market of anticoagulants by states of India in 2017-2019, Rs./pack
Table 11. Assessment of factors of investment attractiveness of the anticoagulant market

All reports